Anglais

Eligibility Criteria

6 Formulaires  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include subject ID, consent group, affection status, and subject source of participants.
    3. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include family ID, father ID, mother ID, and sex of participants
    4. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include sample ID, subject ID, and sample source of participants.
    5. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include subject ID, affection status, age, and duplicated samples of participants.
    6. Study involve identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include sample ID, body site of sample origin, analyte type, tumor or normal tissue, and primary tumor location associated with samples obtained from participants.
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

We have identified 19 HPC families, from a larger set of 307 HPC families, in which ≥ 3 affected relatives were diagnosed with clinically aggressive (defined as Gleason score 8-10, regional or distant stage disease, and/or PC-specific death before age 75) and/or early onset disease (diagnosed at or before age 65 years). To increase the probability of detecting mutations that are truly segregating with disease, the majority of affected men chosen for whole-exome sequencing are ≥ second-degree relatives. In addition, where possible an older, unaffected male relative has been chosen as a 'control' from each family.
Description

We have identified 19 HPC families, from a larger set of 307 HPC families, in which ≥ 3 affected relatives were diagnosed with clinically aggressive (defined as Gleason score 8-10, regional or distant stage disease, and/or PC-specific death before age 75) and/or early onset disease (diagnosed at or before age 65 years). To increase the probability of detecting mutations that are truly segregating with disease, the majority of affected men chosen for whole-exome sequencing are ≥ second-degree relatives. In addition, where possible an older, unaffected male relative has been chosen as a 'control' from each family.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0015576
UMLS CUI [1,2]
C2931456
UMLS CUI [1,3]
C0205449
UMLS CUI [1,4]
C0522476
UMLS CUI [1,5]
C0011900
UMLS CUI [1,6]
C2945759
UMLS CUI [1,7]
C4025592
UMLS CUI [2,1]
C1704788
UMLS CUI [2,2]
C2945759
UMLS CUI [2,3]
C1272646
UMLS CUI [2,4]
C1514819
UMLS CUI [2,5]
C0443203
UMLS CUI [2,6]
C0012634
UMLS CUI [2,7]
C4737841
UMLS CUI [3,1]
C3640077
UMLS CUI [3,2]
C1519210
UMLS CUI [3,3]
C0522476
UMLS CUI [4,1]
C0009932
UMLS CUI [4,2]
C0522477
Retour au début de la page

Similar models

Eligibility Criteria

6 Formulaires
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include subject ID, consent group, affection status, and subject source of participants.
    3. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include family ID, father ID, mother ID, and sex of participants
    4. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include sample ID, subject ID, and sample source of participants.
    5. Study involves identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include subject ID, affection status, age, and duplicated samples of participants.
    6. Study involve identification of hereditary prostate cancer [HPC] susceptibility genes using a novel study design where whole-exome sequencing was undertaken on multiple affected relatives from 19 HPC families with 3 or more affected relatives diagnosed with clinically aggressive and/or early onset prostate cancer. Variables include sample ID, body site of sample origin, analyte type, tumor or normal tissue, and primary tumor location associated with samples obtained from participants.
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Inclusion and exclusion criteria
We have identified 19 HPC families, from a larger set of 307 HPC families, in which ≥ 3 affected relatives were diagnosed with clinically aggressive (defined as Gleason score 8-10, regional or distant stage disease, and/or PC-specific death before age 75) and/or early onset disease (diagnosed at or before age 65 years). To increase the probability of detecting mutations that are truly segregating with disease, the majority of affected men chosen for whole-exome sequencing are ≥ second-degree relatives. In addition, where possible an older, unaffected male relative has been chosen as a 'control' from each family.
Item
We have identified 19 HPC families, from a larger set of 307 HPC families, in which ≥ 3 affected relatives were diagnosed with clinically aggressive (defined as Gleason score 8-10, regional or distant stage disease, and/or PC-specific death before age 75) and/or early onset disease (diagnosed at or before age 65 years). To increase the probability of detecting mutations that are truly segregating with disease, the majority of affected men chosen for whole-exome sequencing are ≥ second-degree relatives. In addition, where possible an older, unaffected male relative has been chosen as a 'control' from each family.
boolean
C0015576 (UMLS CUI [1,1])
C2931456 (UMLS CUI [1,2])
C0205449 (UMLS CUI [1,3])
C0522476 (UMLS CUI [1,4])
C0011900 (UMLS CUI [1,5])
C2945759 (UMLS CUI [1,6])
C4025592 (UMLS CUI [1,7])
C1704788 (UMLS CUI [2,1])
C2945759 (UMLS CUI [2,2])
C1272646 (UMLS CUI [2,3])
C1514819 (UMLS CUI [2,4])
C0443203 (UMLS CUI [2,5])
C0012634 (UMLS CUI [2,6])
C4737841 (UMLS CUI [2,7])
C3640077 (UMLS CUI [3,1])
C1519210 (UMLS CUI [3,2])
C0522476 (UMLS CUI [3,3])
C0009932 (UMLS CUI [4,1])
C0522477 (UMLS CUI [4,2])
Retour au début de la page